Is oxidative stress of adipocytes a cause or a consequence of the metabolic syndrome?

Leonid N. Maslov, Natalia V. Naryzhnaya, Alla A. Boshchenko, Sergey V. Popov, Vladimir V. Ivanov, Peter R. Oeltgen

A R T I C L E   I N F O

Keywords:
Metabolic syndrome
Oxidative stress
Adipocytes

A B S T R A C T

Metabolic syndrome is accompanied by oxidative stress in animals and humans. The main source of ROS in experimental metabolic syndrome is NADPH oxidase and possibly adipocyte mitochondria. It is now documented that oxidative stress induces insulin resistance of adipocytes and increases secretion of leptin, MCP-1, IL-6, and TNF-α by adipocytes. It was established that oxidative stress induces a decrease in adiponectin production by adipocytes. It has also been shown that obesity itself can induce oxidative stress. Oxidative stress can cause an alteration of intracellular signaling in adipocytes that apparently leads to the formation of insulin resistance of adipocytes. Chronic stress, glucocorticoids, mineralocorticoids, angiotensin-II, TNF-α also play an important role in the pathogenesis of oxidative stress of adipocytes. Oxidative stress is not only a consequence of metabolic syndrome, but also a reason and a foundational link in the pathogenesis of the metabolic syndrome.

Introduction

Metabolic syndrome (MS) is a pathological condition that, according to the International Diabetes Federation (IDF) criteria [1], is characterized by obesity, dyslipidemia, hyperglycemia, high blood pressure. Metabolic syndrome is widespread in both developed and developing countries. For example, in the USA this syndrome occurs in 33% of the adult population [2]. In Germany, metabolic syndrome occurs in 33% of the adult population [2]. In Germany, metabolic syndrome occurs in 19.4% of women and 30.2% of men [3]. In Russia, the incidence of MS in men is 23%, and in women 32.4% [4]. It has also been shown that patients with MS had a fourfold increase in mortality from cardiovascular diseases [5].

The pathogenesis of MS has been intensively studied for almost 30 years. However, the mechanism(s) of this metabolic disturbance remains a mystery in many ways. The intent of this review is to draw the reader's attention to the role of reactive oxygen species (ROS) in the pathogenesis of disturbance of adipocyte metabolic state and, as a consequence, in the mechanism of MS occurrence (see Fig. 1).

Oxidative stress in metabolic syndrome, experimental data

In 2003, Tailor et al. published the results of their experiments on adipocytes isolated from adipose tissue from mice fed on a diet enriched with fat [6]. Such a diet led to the formation of a state similar to MS in humans. Isolated adipocytes were characterized by insulin resistance and a twofold increase in the ROS production. In KKAy strain mice with obesity and type 2 diabetes mellitus, an increase in the malondialdehyde (MDA) level in plasma and white adipose tissue was observed in comparison to C57BL/6 mice (without MS), which had an increase in the plasma H2O2 concentration [7]. The inhibitor of NADPH oxidase (Nox) apocynin reduced the MDA level in white adipose tissue in KKAy mice and did not affect the MDA content in white fat of C57BL/6 mice [7].

Later, Kurata et al. also found [8] that in KKAy mice compared with C57BL/6 mice, an increase in the MDA level in the subcutaneous adipose tissue of these mice was 2 times higher than in the control C57BL/6J mice. In experiments on rats fed a diet with a high fructose content, an increase in the activity of Nox in epididymal adipose tissue was noted [9]. These investigators hypothesized that a high fructose diet contributes to MS. Nox generated a superoxide radical (O2•−) [10]. Farina et al. [11] in experiments with...
Fig. 1. The relationship of metabolic syndrome and oxidative stress. ROS, reactive oxygen species; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α.

rats on a diet with a high fructose content, found Nox activation in adipose tissue and an increase in the level of MDA in blood plasma. It has also been shown that only Nox, but also mitochondria of adipocytes can be a source of ROS [12]. The state which is similar to MS is developed in rats on diet with a sucrose-rich diet for 4 months [13]. These rats have high levels of MDA, protein carbonyl groups and TNF-α in blood plasma. In female rats, MS was caused by ovariectomy and drinking water with sucrose (30%) [14]. Such an effect after 6 months resulted in insulin resistance and obesity. The MDA level in the intra-abdominal fat of these rats was increased by almost 5-fold in comparison with the control group.

Recent data indicate that the source of ROS during experimental MS is Nox and, possibly, mitochondria. However, the reason for increasing lipid peroxidation can be not only enhanced ROS production, but also a decrease in antioxidant protection of the adipocyte. Thus, in KKαy mice with obesity and type 2 diabetes mellitus, compared with C57BL/6 mice, a decrease in the activity of superoxide dismutase (SOD) and glutathione peroxidase in white fat was also noted [7]. Similar changes in the activity of enzymes in the liver and skeletal muscles could not be detected by the authors. It has also been demonstrated that glutathione peroxidase activity was decreased in epididymal fat ob/ob mice [15]. A decrease in the activity of SOD, glutathione peroxidase, and catalase has been observed in the intra-abdominal fat of female rats with MS [14].

The aforementioned studies indicate that experimental induced metabolic syndrome promotes oxidative stress in adipose tissue, due to activation of the ROS production and reduction of antioxidant protection of the adipocyte.

Oxidative stress in metabolic syndrome, clinical data

There are few clinical studies on oxidative stress in patients with MS. Furukawa's research referring to patients with oxidative stress is frequently cited [7]. However, there was no data on patients with MS in the article since only healthy volunteers and people with obesity without diabetes mellitus and cardiovascular diseases were included in the study. Since one of the symptoms of MS is arterial hypertension [1], the exclusion of cardiovascular disease suggests that patients with MS may have been excluded from the study. However, Furukawa et al. did present interesting findings which should be mentioned [7]. These authors found that there was a direct correlation between the level of MDA in blood plasma and the body mass index. In addition, an inverse correlation was found between the MDA level in the blood and the concentration of adiponectin in the plasma [7]. A study in Iran included 37 MS patients and 30 healthy volunteers [16]. The authors were unable to identify differences between groups in regard to MDA and antioxidant activity in serum. However, they were able to detect an increase in the total oxidant status of serum in patients with MS [16].

Our study included patients with MS and volunteers without MS (control group) [17]. The diagnosis of MS was made in accordance with the recommendations of the International Diabetes Federation [1]. The material of the study was visceral adipose tissue obtained during surgical interventions. The level of ROS in adipocytes was determined using the dichlorofluorescein diacetate dye by flow laser cyto-fluorometry on the day of isolation [18]. The results were expressed in relative units (R.U.). We found [17] that the production of ROS in adipocytes of visceral fat in patients with MS increased four-fold from $0.074 \pm 0.07 \text{ (M \pm SD, n = 29)}$, in the control group (healthy volunteers) to $0.298 \pm 0.09 \text{ (n = 6)}$ R.U. ($p < 0.05$) in the MS group. The production of ROS in mesenchymal stromal cells of visceral fat in patients with MS was $0.498 \pm 0.08$, and was $0.314 \pm 0.04$ R.U. ($p < 0.05$) in the control group.

The aforementioned studies indicate that the metabolic syndrome promotes oxidative stress in adipose tissue, mainly due to the activation of the products of ROS by adipocytes.

Oxidative stress and obesity

A study performed in China showed that the MDA level in adolescents with obesity is 20% higher ($P < 0.01$) than in adolescents without obesity (control) [19]. In 2012, Karbownik-Lewinska et al. [20] reported that patients which were overweight or obese as compared to volunteers with normal weight that the lipid peroxidation (LPO) level in the serum (MDA, 4-hydroxyalkenali) was increased. The level of LPO products correlated with body weight and body mass index. Similarly, it was demonstrated that in children and adolescents with insulin resistance and obesity without diabetes mellitus that the serum MDA level was increased 3.6-fold [21]. In patients with obesity and type 2 diabetes, the level of leptin (one of the main adipokines) in serum is doubled, and the MDA concentration is increased by 32% compared to the control group (without obesity and diabetes) [22]. In a study performed by Becer and Çrakoğlu [23] included 150 obese patients and 120 volunteers with normal weight. The body mass index in obese patients was 35, the level of total cholesterol was increased, HOMA-IR (homeostatic model assessment-insulin resistance) was 2 fold higher than in the control group (patients without obesity). The concentration of leptin in the blood plasma of obese patients was 3 times higher than in the control group [23]. The MDA level in the serum of obese patients was almost 2 fold higher than in the control group. It should be noted that patients with obesity included in this study, according to IDF criteria, closely matched MS patients, however they did not have arterial hypertension.
Thus, obesity itself can cause oxidative stress. However, it should be noted that in these studies there was no attempt to evaluate the production of ROS by fatty tissue or to determine the source of MDA in the blood of obese patients.

Oxidative stress, as a cause of impaired secretion of adiponectin, leptin, MCP-1, IL-6, TNF-α by fat tissue

It has been shown that the level of leptin was increased in the blood of MS patients in comparison with volunteers without MS [24,25,26] while the concentration of adiponectin was decreased [24,26,27]. Many researchers [25,28,29,30] feel this is directly related to the pathogenesis of MS and its associated complications. Both hormones are synthesized by adipocytes [28]. In patients with MS, the level of proinflammatory cytokines was increased: MCP-1 (monocyte chemoattractant protein 1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [24,31,32,33]. It is believed that these cytokines are synthesized by macrophages of adipose tissue [28] and are involved in the pathogenesis of MS [30].

In experiments on murine pre-adipocyte 3T3-L1 culture, oxidative stress has been shown to decrease the secretion of adiponectin [34]. In 2006, Chen et al. [35], performing experiments with of pre-adipocyte 3T3-L1 culture, found that ROS reduced the expression of adiponectin mRNA. In another study, 3T3-L1 pre- adipocytes were exposed to oxidative stress by adding H2O2 or glucose oxidase to the incubation medium [36]. This causes a decrease in the adiponectin level in adipocytes and increases the production of TNF-α and IL-6. Reduction in the expression of adiponectin mRNA in the pre-adipocyte 3T3-L1 culture after oxidative stress was observed by other investigators [37]. In 2015, Pan et al. [38] found that H2O2 reduced adiponectin production by 3T3-L1 adipocytes by a factor of 2 and contributed to a 3-fold increase in the synthesis of TNF-α and IL-6. Oxidative stress caused by the addition of H2O2 to the incubation medium of 3T3-L1 pre-adipocytes caused an increase in the mRNA levels of leptin, IL-6 and MCP-1 (monocyte chemoattractant protein 1), and an increase in the secretion of these proteins by adipocytes. Especially noticeable was an almost 3-fold increase in secretion of IL-6 [39]. The ability of H2O2 to induce an increase in the mRNA of levels of TNF-α, IL-6, MCP-1 in 3T3-L1 adipocytes while reducing the amount of adiponectin mRNA and decreasing the concentration of this adipokine in the incubation medium was noted by other authors [40].

Thus, it has now been shown that oxidative stress promotes a reduction of adiponectin production and an increase in the synthesis and secretion of leptin, MCP-1, IL-6 and TNF-α by adipocytes.

Oxidative stress and intracellular signaling

In 2003, Talior et al. [6] found that high-fat feed promotes the activation of protein kinase G8 (PKC-δ), the same effect was exerted by H2O2. In experiments with 3T3-L1 adipocytes, it was shown that H2O2 promotes the activation of a number of kinases: Akt (anti-apoptotic kinase), JAKs (Janus kinases), ERK1/2 (extracellular signal-regulated kinase) [41]. Simultaneously, the transcription factor STAT (signal transduced and activator of transcription) is activated. The authors obtained data that the decrease in adiponectin secretion under oxidative stress is associated with activation of Akt, JAK/STAT, and an increase in IL-6 production is a result of an increase in the activity of Akt, JAK/STAT and ERK1/2 [41]. It was found that ROS can not only activate but inhibit signaling [40,42]. Thus, oxidative stress has been shown to reduce insulin-induced activation of protein kinase B (Akt kinase) and PI3 kinase (phosphatidylinositol 3-kinase) in 3T3-L1 adipocyte culture, which, according to the authors, contributes to the disruption of translocation of GLUT4 (Glucose transporter) into cellular membrane [42]. In this connection, it should be noted that PI3K plays an important role in insulin-induced signaling [43]. In experiments with 3T3-L1 adipocytes, it was shown that H2O2 inhibits insulin-induced phosphorylation of the insulin receptor and phosphorylation (activation) of Akt [40]. The phosphorylation of JNK, on the contrary, enhanced.

In experiments with young mice deletion of the gene encoding PKC-δ was deleted specifically in muscle using Cre-lox recombination. It was shown that the deletion of the gene encoding PKC-δ promotes the formation of insulin resistance [44]. In 2011, Bezy et al. [45] received more revealing data. They found that expression of PKC-δ mRNA and PKC-ε was increased in the liver of obese patients compared to people with normal weight. In mice with a liver-specific disturbance of PKC-δ expression, an increase in glucose tolerance, an increase in insulin sensitivity, and an increase in insulin signaling in hepatocytes was observed [45]. Specific liver overexpression of PKC-δ, on the contrary, led to the formation of a state similar to metabolic stress.

The aforementioned data indicate that oxidative stress caused a disturbance of insulin-dependent stimulation of PI3K, while the activity of JNK and PKC-δ in adipocytes increased. Reduced PI3K activity, which is a key enzyme in the insulin-dependent signaling, undoubtedly plays an important role in the formation of ROS-induced insulin resistance. An increase in the activity of PKC-δ in oxidative stress, apparently, also has a direct bearing on the formation of MS. The role of other kinases in regulating the sensitivity of cells to insulin has yet to be completely delineated.

Oxidative stress, as a cause of insulin resistance of adipocytes

Thus, oxidative stress can cause the formation of insulin resistance of adipocytes. In 1997, in experiments with the culture of 3T3-L1 adipocytes, it was shown that oxidative stress leads to a decrease in insulin-dependent glucose transport to the cell [46]. In experiments with 3T3-L1 adipocytes, it was shown that insulin causes translocation into the GLUT4 cell membrane [47], which leads to an increase in glucose transport to the cell. Oxidative stress led to disruption of this process. In 2003, Tailor et al. [6] have shown that oxidative stress in vivo also contributes to the formation of insulin resistance of adipocytes. The authors found that mice fed for 4 months on a high fat content diet became obese and developed an insulin resistant state similar to MS. Adipocytes were isolated from epididymal fat. It turned out that in the presence of glucose the ROS production by adipocytes of animals with MS increased almost 2-fold compared to the adipocytes of healthy mice [6]. It was also shown that H2O2 contributes to the disturbance of glucose uptake of 3T3-L1 adipocytes [36,48]. If ROS is really involved in the pathogenesis of MS, then antioxidants should have a positive effect on the course of MS.

In 2009, research results were published that were performed on high-fat diet-induced insulin resistance rats [49]. It turned out that the antioxidant SS31 contribute to decline the glucose and insulin levels in the blood after oral intake of glucose. In a study that was performed by Gao et al. [50], it was shown that flavonoids, which are natural antioxidants, decreased serum MDA levels, improved insulin resistance, ameliorated lipid disorders in high fat diet fed rats as obesity model and KK-ay mice as diabetic model. In 2009, the results of a study were published that included 5220 adult volunteers without MS who received natural antioxidants (vitamins C and E, β-carotene, zinc, and selenium) for 7.5 years [51]. The risk of MS was assessed. It has been established that there is no benefit or adverse effect of multiple antioxidant supplementation on MS incidence. It has been found that adipocyte-specific deficiency of Nox-4 delays the onset of insulin resistance in mice with a high fat/high sucrose diet [52]. Recently, in experiments with mice with a high fat/high sucrose diet, it has been shown that overexpression of genes encoding catalase and SOD improved insulin sensitivity of adipocytes in comparison with adipocytes of wild type of mice [53]. In contrast, ROS-augmented mice, in which glutathione was depleted specifically in adipocytes, exhibited deteriorated insulin sensitivity of adipocytes.

Thus, oxidative stress can cause the formation of insulin resistance...
Pathogenesis of oxidative stress and insulin resistance of adipocytes

The pathogenesis of the oxidative stress of adipocytes in MS is still a mystery. In 2003, Tailor et al. [6] have shown that the oxidative stress of isolated adipocytes of mice with MS is noted only in the presence of glucose and the resulting hyperglycemia may be the cause of oxidative stress. It is believed that the cause of oxidative stress in MS may be an increase in blood and tissue free fatty acid levels in patients with metabolic syndrome [55]. It has also been documented that TNF-α, whose level is increased in the blood of MS patients, can cause oxidative stress of adipocytes [56,57]. However, there is no conclusive evidence that hyperglycemia, dyslipidemia or elevated TNF-α levels are the primary cause of oxidative stress and subsequent insulin resistance in MS formation. We noted above that oxidative stress induces activation of PKC-δ, which in turn activates Nox, which synthesizes O₂⁻ [58]. Thus, a positive feedback loop can be formed. Oxidative stress increases the TNF-α production, which, in turn, ensures the enhancement of ROS production. Oxidative stress stimulates PKC-δ, it also activates Nox, which in turn causes an increase in O₂⁻ production. However, it is still unclear if this process occurs in vivo.

We concur with Eriksson’s hypothesis [59] that the primary cause of insulin resistance, dyslipidemia in MS is chronic stress. This hypothesis is confirmed by the data of clinical observations [60]. Indeed, clinical data suggest a positive effect of losartan, an angiotensin II receptor antagonist, on MS course [61]. It has also been documented that the mineralocorticoid receptor antagonist eplerenone reduces insulin resistance and adipocyte dysfunction in ob/ob and db/db mice with a dysmetabolic state similar to MS [9]. In experiments on 3T3-L1-adipocytes, it has been shown that dexamethasone can induce insulin resistance [62]. The glucocorticoid receptor antagonist RU486 has been shown to reduce dysfunction of adipose tissue in DahlS.Z-Lepr (fa)/Lepr (fa) rats with MS [63].

Conclusion

The presented data indicate that oxidative stress causes insulin resistance of adipocytes, and contributes to increased secretion of leptin, IL-6, TNF-α by adipocytes. The impact of the resulting ROS leads to decreased adipocyte secretion of adiponectin. It is now documented that obesity itself can cause oxidative stress. The aforementioned studies indicate that a positive feedback loop can be formed: oxidative stress increases the production of TNF-α, which, in turn, ensures the enhancement of AFK production. Oxidative stress also stimulates PKC-δ, and activates Nox, which causes an increase in O₂⁻ production. However, it is still unclear whether these processes occur in vivo. Oxidative stress can cause the formation of insulin resistance of adipocytes. Oxidative stress can also cause impaired insulin-dependent stimulation of PI3K, while the activity of JNK and PKC-δ in adipocytes is increased. Reduction of PI3K activity and stimulation of PKC-6 of adipocytes in oxidative stress seems to have a direct bearing on the formation of the metabolic syndrome. We hypothesize that chronic stress, glucocorticoids, mineralocorticoids, angiotensin II, TNF-α play an important role in the pathogenesis of oxidative stress of adipocytes. The presented data suggest that oxidative stress is not only a consequence of MS, but also a link in the pathogenesis of MS. Our knowledge of the pathogenesis of metabolic syndrome could be greatly expanded by the in vitro studies of adipocytes derived from patients with MS. These studies are necessary to find the source of ROS in patients with MS, but also to determine which pharmacological agents are capable of reducing ROS production by adipocytes in patients with MS. This knowledge would be a great benefit in developing new approaches to MS therapy.

Source of financing

The article was prepared within the framework of the state task AAAA-A15-115120910024-0.

Conflict of interest

There is no conflict of interest.

References

[1] Beck-Nielsen H. Introduction and definition of the metabolic syndrome. In: Beck-Nielsen H, editor. The metabolic syndrome: pharmacology and clinical aspects. Wien: Springer-Verlag; 2013. p. 1-6.
[2] Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syn-
drome in the United States, 2003–2012. JAMA 2015;318(19):1973–4.
[3] Block A, Schipf S, Van der Auwera S, Hannemann A, Nauck M, John U, et al. Sex-
and age-specific associations between major depressive disorder and metabolic syndrome in two general population samples in Germany. Nord J Psychiatry 2016;70(8):611–20.
[4] Milrozanov BM, Seliatitkisova VG, Nikolaev IA, Lutov IV. The prevalence of me-
tabolic syndrome in an organized population. Klin Med (Mosk) 2012;90(11):47–50.
[5] Ioannou A, Almgren P, Tuomi T, Forsén B, Lahlé T, Nissén M, et al. Cardiovascular morbidly and mortality associated with the metabolic syndrome. Diab Care 2001;24(4):683–9.
[6] Tailor I, Varkoni M, Bhasan N, Eldar-Finkelman H. Increased glucose uptake pro-
motes oxidative stress and PKC-α activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 2003;285(2):E292–302.
[7] Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress and its impact on metabolic syndrome. J Clin Invest 2004;114(12):1752–61.
[8] Kurata A, Nishizawa H, Kihara S, Maeda N, Sonomda O, Okada T, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ame-
lorates adipocytokine dysregulation. Kidney Int 2006;70(10):1717–24.
[9] Hirata A, Maeda N, Hiuge A, Hibiuse T, Fujita K, Okada T, et al. Blockade of mi-
neralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84(1):164–72.
[10] Marcus Y, Shefer G, Sasson K, Cohen F, Limor R, Pappo O, et al. Angiotensin I–7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes 2013;62(4):1211–30.
[11] Farina JP, García ME, Alzamendi A, Giovambattista A, Marra CA, Spinelli E, et al. Antioxidant treatment prevents the development of fructose-induced abdominal adipose tissue dysfunction. Clin Sci (Lond) 2013;125(2):87–97.
[12] Wang GH, Wang CC, Huang HC, Wei YH. Mitochondrial dysfunction leads to im-
pairment of insulin sensitivity and adiponectin secretion in adipocytes. FERS J 2013;280(4):1039–50.
[13] Illescas PG, Álvarez SM, Selencig AC, Ferreira MDR, Gíménez MS, Lombardo YB, et al. Dietary soy protein improves adipose tissue dysfunction by modulating parameters related with oxidative stress in dyslipidemic insulin-resistant rats. Biomed Pharmacother 2017;88:1008–15.
[14] Guerra RC, Zutiaga-Muñoz A, Guernier Lars V, Díaz-Díaz E, Tena Betancourt CA, Pérez-Torres I. Modulation of the activities of catalese, Cu-Zn, Mn superoxide dis-
mutase, and glutathione peroxidase in adipocyte from ovarianised female rats. With metabolic syndrome. Int J Endocrinol 2014;2014:175080.
[15] Kobayashi H, Matsuda M, Fukuhara A, Komuro R, Shimomura I. Dysregulated glutathione metabolism links to impaired insulin action in adipocytes. Am J Physiol Endocrinol Metab 2009;296(6):E1326–34.
[16] Hatami M, Saidijam M, Yadegarzadari R, Borzuie S, Soltanian A, Arian MS, et al. Peroxisome proliferator-activated receptor-γ gene expression and its association with oxidative stress in patients with metabolic syndrome. Chonnam Med J 2016;52(3):201–6.
[17] Prokudina ES, Maslov LN, Ivanov VV, Bespalova ID, Pismenniy DS, Voronov NS. The role of reactive oxygen species in the pathogenesis of adipocyte dysfunction in metabolic syndrome. Prospects of pharmacological correction. Vestn Ross Akad Med Nauk 2017;72(11):11–6.
[18] Model MA, Kukuruga MA, Todd RF. A sensitive flow cytometric method for mea-
suring the oxidative burst. J Immunol Meth 1997;202(2):105–11.
[19] Sun M, Huang X, Yan Y, Chen J, Wang Z, Xie M, et al. Rac1 is a possible link between obesity and oxidative stress in Chinese overweight adolescents. Obesity (Silver Spring). 2012;20(11):2233–40.
[20] Karbowiak-Lewinska M, Soszlkand J, Kokozi-Bińska A, Stępińska A, Zasadzka K, Gęzga A, et al. Direct contribution of obesity to oxidative damage to macro-
molecules. Neuro Endocrinol Lett 2012;33(4):453–61.
[21] Habib SA, Saad EA, Elsharkawy AA, Atta ZR. Pro-inflammatory adipocytokines,
oxidative stress, insulin, Zn and Ca: interrelations with obesity in Egyptian non-diabetic obese children and adolescents. Adv Med Sci 2015;60(2):179–85.

[22] Pandey G, Shihabudeen MS, David HP, Thirumurugan E, Thirumurugan K. Association between hyperleptinemia and oxidative stress in obese diabetic subjects. J Diab Metab Disord 2015;14:24.

[23] Becker E, Çarkolü A. Association of the A1a16Val MnSNP gene polymorphism with plasma leptin levels and oxidative stress biomarkers in obese patients. Gene 2015;568(1):35–9.

[24] Kim SH, Chung JH, Song SW, Jung WS, Jung HN. Relationship between deep subcutaneous abdominal adipose tissue and metabolic syndrome: a case control study. Diabetol Metab Syndr 2016;8:10.

[25] Velarde GP, Sherazi S, Kraemer DF, Bravo-Jaimes K, Butterfield R, Amico T, et al. Clinical and biochemical markers of cardiovascular structure and function in women with the metabolic syndrome. Am J Cardiol 2015;116(11):1705–10.

[26] Lee SW, Jo HH, Kim MR, Kim JH, You YO. Association between osteocalcin and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet 2015;292(3):673–81.

[27] Yoon CY, Kim YL, Han SH, Yoo TH, Sung SA, Chung WK, et al. Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study. Diabetol Metab Syndr 2016;8:75.

[28] Miliar B, Marc J. New insights into adipose tissue dysfunction in insulin resistance. Clin Chem Lab Med 2011;49(12):1925–35.

[29] Murdolo G, Barnolini D, Tortosini C, Piroddi M, Iuliano L, Galli F. Lipokines and oysterols: novel adipose-derived lipid hormones linking adipose dysfunction and insulin resistance. Free Radic Biol Med 2013;65:811–20.

[30] Nolan JJ, O’Gorman DJ. Pathophysiology of the metabolic syndrome. In: Beck-Nielsen H, editor. The metabolic syndrome: pharmacology and clinical aspects. Wien: Springer-Verlag; 2013. p. 17–42.

[31] González-Jimenez E, Schmidt-Riiovalle J, Sinauosa L, Carmen Valenzula M, Perezos JNS. Predictive value of ceruloplasmin for metabolic syndrome in adolescents. BioFactors 2016;42(2):163–70.

[32] Christiani U, Gazimierz AE, Nicholas AA, Christian MC, Obiefuna AI. Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndrome. Niger Med J 2016;57(1):64–8.

[33] Mirhafez SR, Pashakhoosh A, Avan A, Emamly H, Moeezi A, Mohabati M, et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr 2015;113(12):1911–9.

[34] Joares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Bouzaidi-Tiali N, Lagarde M, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38(7):882–9.

[35] Chen B, Lam KS, Wang Y, Wu D, Lame MC, Shen J, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006;341(2):549–56.

[36] Monickaraj F, Aravind S, Nandhini P, Prabu P, Sathishkumar C, Mohan V, et al. Accelerated fat cell aging links oxidative stress and insulin resistance in adipocytes. J Biosci 2013;38(11):113–22.

[37] Fukushima M, Okamoto Y, Katsumata H, Ishikawa M, Iishi S, Okamoto M, et al. Growth hormone ameliorates adipose dysfunction during oxidative stress and inflammation and improves glucose tolerance in obese mice. Horm Metab Res 2014;46(9):565–62.

[38] Pan Y, Qiao QY, Pan LH, Zhou DC, Hu C, Gu HF, et al. Losartan reduces cardiac insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes 2015;123(3):170–7.

[39] Kowalska K, Olejnik A. Cranberries (Oxycoccus quadripetalus) inhibit pro-inflammation and ROS production in 3T3-L1 adipocytes. Arch Med Res 2015;46(9):656.

[40] Chen B, Wei J, Wang W, Cui G, Zhao Y, Zhu X, et al. Pan Y, Qiao QY, Pan LH, Zhou DC, Hu C, Gu HF, et al. Losartan reduces insulin resistance in both rodents and humans. J Clin Invest 2011;121(6):2504–17.

[41] Rudich A, Kozlovska N, Potashnik R, Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 1997;272(5 Pt 1):E935–40.

[42] Rudich A, Tirosch A, Potashnik R, Hem R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998;47(10):1562–9.

[43] Guo H, Ling W, Wang Q, Liu C, Hu Y, Xia C, Maiman 3-glycoside protects 3T3-L1 adipocytes against H2O2 or TNF-α-induced insulin resistance by inhibiting e-NOS/TH2-terminal kinase activation. Biochem Pharmacol 2008;75(6):1393–401.

[44] Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009;119(3):573–81.

[45] Gao M, Zhao Z, Lv P, Li Y, Gao J, Zhang M, et al. Quantitative combination of natural anti-oxidants prevents metabolic syndrome by reducing oxidative stress. Redox Biol 2015;6:206–17.

[46] Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, et al. Predictive value of ceruloplasmin for metabolic syndrome in adults. Am J Clin Nutr 2009;89(2):329–35.

[47] Kameji H, Mochizuki K, Miyoshi N, Goda T. β-Carotene accumulation in 3T3-L1 adipocytes inhibits the expression of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α. Nutrition 2010;26(11–12):1151–6.

[48] Yen GC, Chen YC, Chang WT, Hsu CL. Effects of polyphenolic compounds on tumor necrosis factor-α (TNF-α)-induced changes of adiponectin and oxidative stress in 3T3-L1 adipocytes. J Agric Food Chem 2011;59(2):586–51.

[49] Inoguchi T, Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005;6(4):495–501.

[50] Ericksen JW. Metabolic stress in insulin’s target cells leads to ROS accumulation – a hypothetical common pathway causing insulin resistance. FEBS Lett 2010;581(19):3734–42.

[51] Kazakov P, Kyriazopoulou V, Michalaki L, Ierodiaconou V, Pyrogiannis A, Habeos L. Activated hypothalamic pituitary adrenal axis in patients with metabolic syndrome. Horm Metab Res 2012;44(11):839–44.

[52] Chow CL, Lin H, Chen JS, Fang TC. Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats. PLoS One 2012;7(7):e198712.

[53] Nakazawa K, Matusuka N, Takeda Y, Ito S, Sano Y, Yamada Y, et al. Attenuation of cold-stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr Diab 2016;6:e207.